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ABSTRACT
Whooping cough/pertussis is a respiratory infection caused by the bacteria Bordetella pertussis and Bordetella parapertus-
sis. The World Health Organization (WHO) has identified whooping cough as one of the least controlled diseases in all age 
groups. Clinically, the catarrhal phase manifests itself as flu-like, nonspecific symptoms: cough, runny nose, mild fever, which, 
regrettably, makes early diagnosis difficult. The severe course is more specific (an audible inspiratory whoop followed by 
paroxysmal cough and vomiting). Currently, in Poland the highest percentage of cases is observed in children aged 0–4 years, 
followed by children over 15 years of age, with peaks among teens and seniors. Notably, hospitalization, morbidity and 
mortality rates are considerable in children (especially infants). Vaccinating pregnant women against pertussis provides 
approximately 90% protection to infants in their first two months of life. It is an effective form of preventing pertussis in 
infants. Moreover, it is safe for pregnant women and their children. The Advisory Committee on Immunization Practices 
(ACIP) recommends Tdap vaccination to every pregnant woman between 27–36 weeks of pregnancy.
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INTRODUCTION
Whooping cough/pertussis is a respiratory infection 
caused by the bacteria Bordetella pertussis and Bordetella 
parapertussis [1]. The infection is spread by droplets (e.g., 
through coughing or sneezing). Although there is an effec-
tive vaccine, the World Health Organization (WHO) identi-
fied whooping cough as one of the least controlled dis-
eases across all age groups. However, the most vulnerable 
groups are young children and adolescents. According to 
the WHO, whooping cough epidemics appear cyclically ev-
ery 3–4 years. Pertussis is highly infectious, with one person 
infecting up to 17 susceptible people, and untreated people 
may be infectious for more than three weeks after the onset 
of cough. The incubation period of pertussis is between 
one and three weeks. Clinically, the milder catarrhal phase 
manifests itself as flu-like, nonspecific symptoms: cough, 
runny nose, mild fever, which, regrettably, makes early di-
agnosis difficult. Conversely, a severe course, called the 
paroxysmal phase is more specific (an audible inspiratory 
whoop followed by paroxysmal cough and vomiting) [1, 2]. 
Early antibiotic therapy may alleviate symptoms (when 
implemented before the onset of the paroxysmal stage). 
It should be noted that vaccination is the most cost-effective 
form of preventing whooping cough epidemics [2].
In Poland, mass vaccination against pertussis was 
launched in 1960. By that time, tens of thousands of cases 
had been reported, with whooping cough being one of the 
most common causes of death in children under the age of 
one. The number of reported cases decreased below 500 per 
year in the 80s. Regrettably, an increase in the incidence 
was recorded in the mid-90s. Therefore, in 2003, a booster 
dose of vaccines was introduced in Poland at six years of 
age. Currently, there is a high incidence of whooping cough 
with the cyclicality of the disease. Year 2012 was a critical 
for 40 years, with 4,684 cases being recorded, including 
1,497 people who required hospitalization. Currently, the 
highest percentage of cases is observed in children aged 
0–4 years, followed by individuals over 15 years of age, with 
peaks among teens and seniors [2–4].
In 2014, a total of 5.1 million cases of whooping cough 
and 85,900 deaths were estimated in children under 
12 months old worldwide. Over 80% of cases and 95% of 
deaths occurred in low- and middle-income countries, where 
vaccination coverage was low [2]. The European Centre for 
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Disease Prevention and Control (ECDC) report on Pertussis 
showed that 35,627 cases of the disease were registered in 
30 European Union/European Economic Area (EU/EEA) coun-
tries in 2018. Young people aged 15 and above accounted 
for 62% of all cases. However, infants constituted the largest 
group at 44.4 per 100,000 population. As of August 2020, 
eight countries implemented a program of the vaccination 
of pregnant women and in five countries the vaccination 
program included a minimum of one booster dose of pertus-
sis vaccination in persons over the age of 18 [5].
An increase in whooping cough incidence has been ob-
served in recent years due to the rapid waning of post-vacci-
nation immunity after vaccination with acellular vaccine in 
comparison with the previously used whole-cell vaccine [6].
WHO IS EXPOSED TO SEVERE AND 
COMPLICATED WHOOPING COUGH?
Whooping cough may occur at any age, but the dis-
ease is especially virulent and life-threatening in infants 
[6]. The manifestations of the disease may be mild in adults 
and adolescents and is often undiagnosed, increasing the 
chances of disease spread in the environment. This, in turn, 
contributes to the possibility of transmitting the infection to 
infants who may not be vaccinated [5]. Children (especially 
infants) are a group in which hospitalization, morbidity and 
mortality rates are particularly high. Non-specific symptoms 
in children make the diagnosis difficult. In young children 
whooping cough may lead to complications such as apnea, 
seizures, encephalopathy, pneumonia and even death [2].
PERTUSSIS PREVENTION IN PREGNANT 
WOMEN
Vaccinating pregnant women against pertussis pro-
vides 90% protection to infants in their first two months of 
life, that is, until they may be vaccinated [2, 7]. Vaccinating 
pregnant women against whooping cough was initiated in 
response to outbreaks after 2010, when an alarming, wor-
rying number of deaths of young children was recorded in 
the US and the UK. In 2015, the WHO recommended that 
pregnant women and infants over six weeks old should 
be vaccinated against whooping cough. It is impossible 
to vaccinate children earlier, as the presence of maternal 
antibodies may suppress post-vaccination immunogenicity. 
Numerous studies showed that the cocoon strategy (vac-
cination of people in direct contact with exposed children) 
and vaccination after delivery were ineffective in protecting 
children [2].
A retrospective cohort study involving 148,981 children 
born in Northern California, the USA, conducted between 
2010 and 2015, revealed that the immunization coverage of 
pregnant women against tetanus, diphtheria and pertussis 
(Tdap) increased from 11.9% in 2010 to 87.4% in 2015, and 
the confirmed vaccine efficacy was 91.4% in infants under 
two months of age [6, 7]. 
In early infancy, when the child may not yet be vaccinat-
ed against pertussis (Tdap) the only protection is provided 
by antibodies passed from the mother during pregnancy [6]. 
If the pregnant woman was not vaccinated against whoop-
ing cough, the level of antibodies drops significantly at six 
weeks of age and is undetectable around four months of 
age [8]. In contrast, pregnant women vaccinated against 
Tdap transmit antibodies to the fetus, so that high levels of 
antibodies to pertussis are maintained in infants up to one 
dose of Tdap vaccine [9]. Numerous researchers empha-
sized that vaccinating pregnant women against whooping 
cough provided a more effective protection for the infant 
than the cocoon strategy in which the closest contacts are 
vaccinated [6, 10–13].
Currently, the only safe vaccines administered to preg-
nant women are acellular vaccines, which contain highly 
purified individual B pertussis components [2]. Infants are 
protected by immunoglobulins that passively pass through 
the placenta or into human milk. The half-life of maternal 
immunoglobulin is 42 days. Numerous studies confirmed 
significantly higher levels of anti-whooping cough immu-
noglobulins in the children of mothers vaccinated during 
pregnancy [14–16].
PERTUSSIS VACCINE SAFETY AND 
EFFECTIVENESS IN PREGNANCY
The latest systematic review of the literature assessing 
the efficacy and safety of pertussis vaccination with Tdap 
during pregnancy, including Medline, Embase and clinical-
trials.gov in 2010–2019, conducted by the Immunization 
Unit of the Koch Institute in Berlin, finally qualified 22 stud-
ies (randomized, cohort, and clinical control). This included 
14 studies on the safety of Tdap in pregnancy and the fetus 
(1,400,000 pregnant women in total) and eight efficacy stud-
ies on the prevention of whooping cough in infants during 
the first three months of life (855,546 mother-infant pairs in 
total) [17]. Those studies showed that vaccination with Tdap 
during pregnancy did not increase the risk of stillbirth [18–
–22], neonatal death [20, 21], preterm birth under 37 weeks 
gestation (interestingly, according to some researchers, the 
frequency of deliveries before 37 weeks was lower among 
women vaccinated against whooping cough during preg-
nancy) [18, 19, 21–26], low birth weight (both under 2500 g 
and under 1500 g) [19, 20, 25] or birth defects [18, 19, 21, 22, 
24, 27] in a child. Safety was also proved as regards the risk 
of pre-eclampsia and eclampsia. Two studies even showed 
a reduction in the risk of pre-eclampsia [20, 23, 25, 27].
Several studies showed a trend towards a slightly 
higher incidence of chorioamnionitis in Tdap-vaccinated 
pregnancies than in unvaccinated women [the relative risk 
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(RR) ranged from 1.04 (95% CI: 0.98–1.11) to 1.53 (95% CI: 
0.80–2.90)], but only in three studies were the estimates 
statistically significant [19, 21, 24, 25]. Four studies assessed 
the incidence of fever after Tdap vaccination in pregnant 
women. In general, fever occurred in 0.03–3% of pregnant 
women and was more common in those vaccinated against 
whooping cough than in unvaccinated ones. The authors 
pointed out, however, that the accepted definition of fever 
varied in different studies [18, 26, 27].
A retrospective cohort study assessed the association 
between the vaccination of pregnant women with Tdap vac-
cine and the subsequent development of autism spectrum 
disorders  (ASD) in children. It included 81,993 children born 
in single pregnancies in 2011–2014 in Kaiser Permanente 
Southern California hospitals. On average, vaccination was 
performed at 28 weeks of gestation. ASD was diagnosed in 
1.6% (1,341) children, and the follow-up period was between 
1.2 and 6.5 years. The study showed that the vaccination of 
pregnant women with Tdap did not increase the risk of ASD 
in the offspring [HR: 0.85 (95% CI: 0.77–0.95)] [28]. A recent 
study by the same researchers, including over 85,000 chil-
dren born in 2011–2014 showed that the vaccination of 
pregnant women with Tdap vaccine at any time during 
pregnancy did not increase the risk of attention deficit hy-
peractivity disorder (ADHD) in their offspring. ADHD was 
diagnosed in 1% (882) of children and there was no cor-
relation between vaccination with Tdap during pregnancy 
and an increased risk of ADHD in the children of vaccinated 
women [HR: 1.0 (95% CI: 0.88–1.14)] [29].
The authors of the study concluded that although fever 
and chorioamnionitis were diagnosed slightly more fre-
quently in women vaccinated with Tdap during pregnancy, 
vaccination was not found to increase the risk of clinically 
significant consequences for the pregnant women and 
their children. Due to the generally low quality of data, the 
authors recommended to continue the monitoring of the 
safety of Tdap in pregnant women, including the occurrence 
of chorioamnionitis and its sequelae [19, 21, 24–27].
Regarding the effectiveness of Tdap vaccination during 
pregnancy, the vaccination was found to reduce the risk of 
developing laboratory-confirmed pertussis by 78–93% [6, 
30–32] in the first two months of life and by 69–91% [30, 31, 33] 
in the first three months. Additionally, having received 
Tdap vaccine up to two years before the current pregnancy 
was also associated with some degree of protection [6].
WHEN TO GET VACCINATED?
Regrettably, no international consensus has been 
reached on the most appropriate time to vaccinate preg-
nant women. Recommendations as to when to vaccinate 
pregnant women vary by organization and range between 
16 and 38 weeks of pregnancy. The Joint Committee on 
Vaccination and Immunization (JVCI, UK) recommended 
vaccinations between 16–32 weeks of gestation (ideally 
after 20 weeks). In contrast, in 2013, the Advisory Committee 
on Immunization Practices (ACIP) issued recommendations 
that recommended the Tdap vaccination of every pregnant 
woman, regardless of the time of the previous vaccination, 
between weeks 27–36 of pregnancy to ensure the maxi-
mum possible transplacental transfer of antibodies [2, 34]. 
In Poland, the Minister of Health identified groups for which 
vaccination against diphtheria, tetanus and pertussis is rec-
ommended. They include, among others, pregnant women 
between 27 and 36 weeks of pregnancy and people from 
the environment of newborns and infants up to 12 months 
of age [35]. A vaccination after 38 weeks of pregnancy may 
not ensure the transfer of antibodies across the placenta, 
so it may be unable to provide the infant with immunity. 
However, it may prevent a pregnant woman from becoming 
ill, which might later protect the child [2].
CONCLUSIONS
According to the ECDC and the WHO pertussis re-
mains a challenge for public health in Europe. Therefore, 
high vaccination coverage is necessary to provide indi-
rect and direct protection to infants and young children, 
i.e., groups that manifest the most severe symptoms. 
Booster doses in adolescents and adults, healthcare profes-
sionals and pregnant women should be considered. The vacci-
nation of pregnant women is effective in preventing pertussis 
in infants and is safe for pregnant women and their children.
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